logo-loader

Summit Therapeutics receives further US$8.8mln boost to antibiotic programme 

Published: 12:55 23 Jan 2020 GMT

Summit Therapeutics PLC -
The latest US cash injection will support a new clinical trial in adolescent patients

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) said the American authorities have increased their financial backing of a programme developing a next-generation antibiotic.

The Biomedical Advanced Research and Development Authority (BARDA) is pumping a further US$8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection (CDI) taking the total value of the award to US$72.5mln.

The latest US cash injection will support a new clinical trial in adolescent patients, which in turn is expected to help with the new drug application for ridinilazole.

“BARDA’s continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population,” said Summit Glyn Edwards.

“We thank BARDA for its commitment to ridinilazole, innovation and public health,” he added.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 20 minutes ago